^

Health And Family

UAE registers China's Sinopharm vaccine, says 86% effective

Agence France-Presse
UAE registers China's Sinopharm vaccine, says 86% effective
This picture taken on November 23, 2020 shows a bottle reading "Vaccine Covid-19" next to Chinese National Pharmaceutical Sinopharm logo.
AFP/Joel Saget

DUBAI, United Arab Emirates — The United Arab Emirates on Wednesday officially registered the coronavirus vaccine produced by Chinese drug giant Sinopharm, saying it was 86 percent effective according to analysis of third-phase trials.

The health ministry "has announced the official registration" of the vaccine, state news agency WAM said, without elaborating on how it would now be used. 

The vaccine has been undergoing third-phase trials in the Emirates since July, and it was approved for emergency use for healthcare workers in September.

"The announcement is a significant vote of confidence by the UAE’s health authorities in the safety and efficacy of this vaccine," WAM said.

UAE health officials have reviewed Sinopharm's interim analysis of the third-phase trials which shows it is 86 percent effective against coronavirus, the report said.

"The analysis also shows the vaccine to have 99 percent seroconversion rate of neutralising antibody and 100 percent effectiveness in preventing moderate and severe cases of the disease.

"Furthermore, the analysis shows no serious safety concerns."

China has four vaccine products in the final stages of development, three of which — including Sinopharm — use an inactivated form of the novel coronavirus to boost immunity.

This means they only need to be refrigerated and can be easily distributed compared to jabs developed by rivals Pfizer and BioNTech or Moderna, which have reported efficacy of 95 percent and 94 percent respectively but need to be transported at minus 70 to 20 degrees Celsius. 

However, Chinese drugmakers have not released any data on their vaccines' safety or efficacy.

Chinese vaccine makers also have chequered reputations, after major scandals at home involving expired or poor quality products. While the government's domestic handling of the virus has won support within China, overseas buyers are cautious.

Chinese vaccine frontrunners Sinovac and Sinopharm have pre-orders for less than 500 million doses in total by mid-November, according to data from London consultancy Airfinity, mostly from countries that have participated in trials.

Two vaccines have undergone third-phase trials in the UAE, the Sinopharm project and Russia's Sputnik-V, named after the Soviet-era satellite.

Dubai ruler Sheikh Mohammed bin Rashid Al-Maktoum said in November that he had received an experimental coronavirus vaccine, joining other top UAE officials to take part in the trials.

COVID-19 VACCINE

NOVEL CORONAVIRUS

UNITED ARAB EMIRATES

As It Happens
LATEST UPDATE: June 16, 2022 - 8:48am

Pharma giants Sanofi and GSK said on July 29, 2020, that they have agreed to supply Britain with up to 60 million doses of a potential COVID-19 vaccine. The agreement covers a vaccine candidate developed by France's Sanofi in partnership with the UK's GSK and is subject to a "final contract."

This thread collects some of the major developments in the search for a vaccine to ease the new coronavirus pandemic. (Main photo by AFP/Joel Saget)

June 16, 2022 - 8:48am

A panel of experts convened by the US Food and Drug Administration unanimously recommends Covid-19 vaccines  for children under five, the final age group awaiting immunization in most countries.

Formal authorizations should follow soon, with the first shots in arms expected early next week, just over a year-and-a-half after the first Covid vaccines were greenlighted for the elderly in December 2020.

"This recommendation does fill a significant unmet need for a really ignored younger population," says Michael Nelson, a professor of medicine at the University of Virginia, one of the 21 experts asked to vote for the milestone meeting. — AFP

June 15, 2022 - 9:24am

A panel of US medical experts recommends the Moderna COVID-19 vaccine for use in children aged six through 17.

Formal authorization should soon follow, at which point families will have a second option against the coronavirus, as Pfizer's vaccine was given the greenlight for teens and younger children last year.

After weighing available data, 22 experts convened by the US Food and Drug Administration unanimously agreed that the known benefits outweighed the known risks when Moderna's vaccine was administered as two shots at the adult dose of 100 micrograms to those aged 12-17, and half of that for children 6-11. — AFP

June 8, 2022 - 10:16am

A panel of experts convened by the US drug regulator recommends the Novavax COVID-19 shot, a late runner in the fight against the virus that could nonetheless play a role in overcoming vaccine hesitancy.

Three vaccines are currently approved in the United States: Pfizer and Moderna, which are based on messenger RNA, and Johnson and Johnson, which recently received a recommendation against broad use becase of links to a serious form of clotting.

Experts voted 21 in favor of the Novavax vaccine, with none against, and one abstention, despite some concerns it may be linked to rare cases of heart inflammation. — AFP

June 4, 2022 - 6:04pm

The Food and Drug Administration voices concern about myocarditis being potentially linked to the Novavax COVID-19 vaccine, just as experts are to weigh its use in the United States. 

The Novavax vaccine is already authorized in other countries, particularly in Europe. In the United States, an independent committee convened at the request of the FDA is to meet Tuesday to evaluate data from the clinical trials of Novavax and give its recommendation. 

In advance of that, the agency published a lengthy document on Friday analyzing these results, as it had done for the three other vaccines already authorized in the country. — AFP

April 14, 2022 - 9:19am

The head of US pharmaceutical giant Pfizer says a COVID-19 vaccine effective against multiple variants is possible before the end of 2022.

Chairman Albert Bourla says the firm was also working on producing a vaccine that could provide good protection for a whole year, meaning people would come back annually for boosters, as with influenza shots.

"I hope, clearly by autumn... that we could have a vaccine" that worked against not only the dominant Omicron but all known variants, he says. — AFP 

Philstar
  • Latest
Latest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

FORGOT PASSWORD?
SIGN IN
or sign in with
no session for state
no session for code
no session for id_token
no session for user